Market Access News | pharmaphorum

News

FDA plan will cut testing requirements for biosimilars

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilar medicines to market as a way to cut US drug prices.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

News

A male HCP discusses treatment with an older male patient

Bayer's prostate cancer drug Nubeqa cleared for NHS use

Thousands of men living with incurable prostate cancer will be able to access an easier-to-tolerate treatment from Bayer, thanks to new NICE guidance.

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

GSK's Blenrep's back in US, but with a narrower label

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed from sale.

News

CHMP backs first drug for lung disease bronchiectasis

Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.

FDA plan will cut testing requirements for biosimilars

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Bayer's prostate cancer drug Nubeqa cleared for NHS use

ICER says US new drug launch prices have risen sharply

GSK's Blenrep's back in US, but with a narrower label

CHMP backs first drug for lung disease bronchiectasis

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks